Given this function of glutamine in providing an essential metabolite for the oncogenic activity of mutant IDH1/IDH2, it is not surprising that BTES, a glutaminase inhibitor, reduced the growth of IDH-mutant AML cells [231]. The gene discussed is IDH2; the disease is acute myeloid leukemia.